Class I phosphoinositide3-‐kinases in immunity…
117
28. Yap, T. A.; Garrett, M. D.;Walton, M. I.; Raynaud, F.; deBono, J. S.; &Workman, P. Targeting
the PI3K-‐AKT-‐mTOR pathway: progress, pitfalls, and promises.
Curr Opin Pharmacol
8
,
393-‐412(2008).
29. Chi, H. Regulationand functionofmTORsignalling inTcell fatedecisions.
Nat Rev Immunol
12
, 325-‐338(2012).
30. Dodson, L. F.; Boomer, J. S.; Deppong, C.M.; Shah, D. D.; Sim, J.; Bricker, T. L.; Russell, J. H.;&
al. Targeted kock-‐in mice expressing mutations of CD28 reveal an essential pathway for
costimulation.
Mol Cell Biol
29
, 3710-‐3721(2009).
31. Dragoi, A.-‐M.; Fu, X.; Ivanov, S.; Zhang, P.; Sheng, L.;Wu, D.; Li, G. C.; &al. DNA-‐PKcs, but not
TLR9, is required for activationofAkt byCpG-‐DNA.
EMBO J
24
, 779-‐789(2005).
32. Bozulic, L.; Surucu, B.;Hynx, D.;&Hemmings, B. A. PKB
α
/Akt1actsdownstreamofDNA-‐PK
in the DNA double-‐strand break response and promotes survival.
Mol Cell
30
, 203-‐213
(2008).
33. Finlay, D.; & Cantrell, D. A. Phosphoinositide 3-‐kinase and the mammalian target of
rapamycinpathways control Tcellmigration.
AnnNYAcadSci
1183
, 149-‐157(2010).
34. Bustelo, X. R. Regulatory and signaling properties of theVav family.
Mol Cell Biol
20
, 1461-‐
1477(2000).
35. Smith, C. I. E.; Islam, T. C.;Mattsson, P. T.;Mohamed, A. J.; Nore, B. F.; &Vihinen,M. TheTec
family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs
inother species.
BioEssays
23
, 436-‐446(2001).
36. Readinger, J. A.; Mueller, K. L.; Venegas, A. M.; Horai, R.; & Schwartzberg, P. L. Tec kinases
regulate T-‐lymphocyte development and function: new insights into the roles of Itk and
Rlk/Txk.
Immunol Rev
228
, 93-‐114(2009).
37. Lee, K.-‐Y.; D'Acquisto, F.; Hayden, M. S.; Shim, J.-‐H.; & Ghosh, S. PDK1 nucleates T cell
receptor-‐inducedsignalingcomplex forNF-‐
κ
Bactivation.
Science
308
, 114-‐118(2005).
38. Nirula, A.; Ho, M.; Phee, H.; Roose, J.; & Weiss, A. Phosphoinositide-‐dependent kinase 1
targets protein kinase A in a pathway that regulates interleukin 4.
J ExpMed
203
, 1733-‐
1744(2006).
39. Zhao, L.;&Vogt, P. K. Class I PI3K inoncogenic cellular transformation.
Oncogene
27
, 5486-‐
5496(2008).
40. Samuels, Y.; &Waldman, T. Oncogenicmutations of PIK3CA inhuman cancers. InRommel,
C.; Vanhaesebroeck, B.; & Vogt, P. K., Editors. In
Phosphoinositide 3-‐kinase in Health and
Disease
; SpringerBerlinHeidelberg, 2010; p. 21-‐41.
41. Gabelli, S.; Huang, C.-‐H.; Mandelker, D.; Schmidt-‐Kittler, O.; Vogelstein, B.; & Amzel, L. M.
Structural effects of oncogenic PI3K
α
mutations. In Rommel, C.; Vanhaesebroeck, B.; &
Vogt, P. K., Editors. In
Phosphoinositide 3-‐kinase in Health and Disease
; Springer Berlin
Heidelberg, 2010; p. 43-‐53.
42. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; & al. High
frequencyofmutationsof thePIK3CAgene inhumancancers.
Science
304
, 554(2004).
43. Sun, M.; Hillmann, P.; Hofmann, B. T.; Hart, J. R.; &Vogt, P. K. Cancer-‐derivedmutations in
the regulatory subunit p85
α
of phosphoinositide 3-‐kinase function through the catalytic
subunit p110
α
ProcNatl AcadSci USA
107
, 15547-‐15552(2010).
44. Soler, A.; Serra, H.; Pearce, W.; Angulo, A.; Guillermet-‐Guibert, J.; Friedman, L. S.; Viñals, F.;
& al. Inhibition of the p110
α
isoform of PI 3-‐kinase stimulates nonfunctional tumor
angiogenesis.
J ExpMed
210
, 1937-‐1945(2013).
45. Angulo, I.; Vadas, O.; Garçon, F.; Banham-‐Hall, E.; Plagnol, V.; Leahy, T. R.; Baxendale, H.; &
al. Phosphoinositide 3-‐kinase
δ
gene mutation predisposes to respiratory infection and
airwaydamage.
Science
342
, 866-‐871(2013).
46. Fransson, S.; Uv, A.; Eriksson, H.; Andersson, M. K.;Wettergren, Y.; Bergo, M.; &Ejeskar, K.
p37
δ
is anewisoformof PI3Kp110
δ
that increases cell proliferationand is overexpressed
in tumors.
Oncogene
30
, Adv. OnlinePub. (2011).
47. Papakonstanti, E. A.; Ridley, A. J.; &Vanhaesebroeck, B. The p110
δ
isoformof PI 3-‐kinase
negativelycontrolsRhoAandPTEN.
EMBO J
26
, 3050-‐3061(2007).
48. Tzenaki, N.; Andreou, M.; Stratigi, K.; Vergetaki, A.;Makrigiannakis, A.; Vanhaesebroeck, B.;
&Papakonstanti, E. A. High levels of p110
δ
PI3K expression in solid tumor cells suppress
PTENactivity, generating cellular sensitivity top110
δ
inhibitors throughPTENactivation.
FASEB J
26
, 2498-‐2508(2013).
